COMP <GO>
RYTM vs JNJ // FREE CASH FLOW YIELD
Rhythm Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: RYTM 4
— JNJ 9
▲ FREE CASH FLOW YIELD LEADER: JNJ
LAST: $92.57 (-0.54%) • MKT CAP: $6.41B
fcf-yield
-1.82%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
fcf-yield
2.97%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RYTM VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RYTM | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.70% | 67.90% | +21.80 | RYTM | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.60% | 25.50% | -55.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -1.82% | 2.97% | -4.79 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -0.10% | 28.50% | -28.60 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 45.80% | 6.00% | +39.80 | RYTM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.33 | 5.59 | +8.74 | RYTM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.20% | -0.40 | RYTM | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.3 | 60.4 | -10.10 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.08 | -0.12 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 23.0x | +10.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.41B | $662.49B | -$656.08B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RYTM REV | JNJ REV | RYTM GROSS % | JNJ GROSS % | RYTM FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $189.8M | $94.19B | 89.7% | 67.9% | -$116.6M | $19.70B |
| FY 2024 | $130.1M | $88.82B | 89.7% | 69.1% | -$113.9M | $19.84B |
| FY 2023 | $77.4M | $85.16B | 44.0% | 44.0% | -$139.6M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RYTM // BETA 0.96
JNJ // BETA 1.08